EU antitrust regulators are set to accept South African pharmaceutical company Aspen’s concessions aimed at ending a three-year long investigation that could lead to a hefty fine, two people familiar with the matter said.
Aspen last year offered to cut prices by an average of 73% for six off-patent cancer drugs after the European Commission voiced concerns that it may have charged excessive prices for drugs used for cancer patients.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
